# US 2021/0174966 A1 · Predicting and preventing hypoglycemia in patients having type 1 diabetes during periods of incognizance using big data analytics and decision theoretic analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0174966 A1
- Document ID: US20210174966A1
- Status: Published application
- Kind: A1
- Application number: 17/114,433
- Filed: 2020-12-07
- Published: 2021-06-10
- Earliest claimed: 2019-12-05
- Applicants: Oregon Health & Science University
- Inventors: Peter G. Jacobs; Clara Mosquera-Lopez; Nichole Tyler; Robert Dodier; Jessica Castle; Joseph E. Youssef; Leah Wilson
- Web page: https://patentgrep.com/patent/US20210174966A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- G06N 3/08: Learning methods
- G06N 3/09: Supervised learning
- G06N 3/0985: Hyperparameter optimisation; Meta-learning; Learning-to-learn
- G06N 20/10: using kernel methods, e.g. support vector machines [SVM]
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 20/17: delivered via infusion or injection
- G16H 20/30: relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
- G16H 20/60: relating to nutrition control, e.g. diets
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/50: for simulation or modelling of medical disorders
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Disclosed are techniques for supporting glucoregulatory management decisions using a decision support recommender to predict an occurrence of a hypoglycemic event in an incognizant living subject. Glucose management data is obtained from a living subject. It is processed as prescribed by a feature extractor to generate a set of glucoregulatory feature values. The glucoregulatory feature values are applied as prescribed by the feature extractor to a hypoglycemia prediction model. The hypoglycemia prediction model is formulated to predict the occurrence of a hypoglycemic event during a period of incognizance of the living subject. A glucoregulatory management recommendation is generated as prescribed by the decision support recommender if the hypoglycemia prediction model predicts the occurrence of a hypoglycemic event during the period of incognizance.

## Claims

### Claim 1

A method for supporting glucoregulatory management decisions using a decision support recommender to predict an occurrence of a hypoglycemic event in an incognizant living subject, comprising:
receiving glucose management data obtained from a living subject;
processing the glucose management data as prescribed by a feature extractor to generate a set of glucoregulatory feature values;
applying the glucoregulatory feature values as prescribed by the feature extractor to a hypoglycemia prediction model, the hypoglycemia prediction model being formulated to predict the occurrence of a hypoglycemic event during a period of incognizance of the living subject; and
generating a glucoregulatory management recommendation as prescribed by the decision support recommender if the hypoglycemia prediction model predicts the occurrence of a hypoglycemic event during the period of incognizance.

### Claim 2 (depends on 1)

The method of claim 1, in which the decision support recommender is trained using a supervised training process.

### Claim 3 (depends on 2)

The method of claim 2, in which the supervised training process includes one or both of a regression-based process or a classifier-based process.

### Claim 4 (depends on 3)

The method of claim 3, in which the regression-based process is a support vector regression or a neural-network regression.

### Claim 5 (depends on 3)

The method of claim 3, in which the classifier-based process is at least one of a random forest process, a decision tree process, and a support vector machine process.

### Claim 6 (depends on 2)

The method of claim 2, in which the supervised training process generates a set of hyperparameter values wherein hyperparameter values in the set are optimized by a cross-validation optimization process.

### Claim 7 (depends on 6)

The method of claim 6, in which the set of hyperparameter values includes a tolerance hyperparameter and a regularization hyperparameter.

### Claim 8 (depends on 1)

The method of claim 1, in which the supervised training process includes at least one of an insulin-metabolism impact model, a glucagon-metabolism impact model, and a nutrient-metabolism impact model.

### Claim 9 (depends on 8)

The method of claim 8, in which the nutrient-metabolism impact model includes a carbohydrate model, a protein model, or a fats model.

### Claim 10 (depends on 1)

The method of claim 1, in which the supervised training process includes an exercise-metabolism impact model.

### Claim 11 (depends on 1)

The method of claim 1, in which the supervised training process includes a stress-metabolism impact model.

### Claim 12 (depends on 1)

The method of claim 1, in which the supervised training process includes a sleep-metabolism impact model.

### Claim 13 (depends on 1)

The method of claim 1, in which the supervised training process uses virtual patient data, the virtual patient data including single or multiple hormone virtual patient data.

### Claim 14 (depends on 13)

The method of claim 13, in which the virtual patient data are generated using a glucoregulatory model.

### Claim 15 (depends on 1)

The method of claim 1, in which the supervised training process uses validated or actual patient data.

### Claim 16 (depends on 1)

The method of claim 1, in which the hypoglycemia threshold value is selected using a decision under uncertainty theoretic.

### Claim 17 (depends on 16)

The method of claim 16, in which the decision under uncertainty theoretic calculates an outcome benefit.

### Claim 18 (depends on 17)

The method of claim 17, in which the outcome benefit is calculated using a blood glucose index.

### Claim 19 (depends on 16)

The method of claim 16, in which the decision under uncertainty theoretic has first and second expected net benefit values wherein the first and second expected net benefit values represent, respectively, the expected net benefit of predicting hypoglycemia or predicting the absence of hypoglycemia, and the hypoglycemia threshold value correlates with the first expected net benefit value being greater than the second expected net benefit value.

### Claim 20 (depends on 16)

The method of claim 16, in which the decision under certainty theoretic is a process comprising:
selecting a BTP value, the BTP value being representative of the benefit of correctly predicting a hypoglycemic event;
selecting a BTN value, the BTN value being representative of the benefit of correctly predicting the absence of a hypoglycemic event;
selecting a BFP value, the BFP value being representative of the benefit of incorrectly predicting a hypoglycemic event;
selecting a BFN value, the BTP value being representative of the benefit of incorrectly predicting the absence of a hypoglycemic event;
calculating a p(IH)Crit value, the p(IH)Crit value representative an expected net benefit for predicting hypoglycemia that is greater than the expected net benefit of predicting the absence of hypoglycemia, wherein: p(IH)Crit>((BTN−BTP)/(BFP−BFP+BTP−BFN));
calculating a gTH value wherein p(IH)Crit=0.5×[1+erf(x−(gTH+μe)/√2σe)] where μe and σe are the average and standard deviation of errors made by the hypoglycemia prediction model; and
setting the hypoglycemia threshold value equal to the gTH.

### Claim 21 (depends on 20)

The method of claim 20, in which the BTP, BTN, BFP, and BFN values are selected using LBGI and HBGI benefit estimates wherein Bj=(LBGIni−LBGIi)+(HBGIni−HBGIi) where j∈{TF, FP, FN, TN}.

### Claim 22 (depends on 1)

The method of claim 1, in which the glucose management data includes one or more of the following: historical values related to insulin therapy, glucagon therapy, nutrients, meals, physical activity, and sleep of the living subject.

### Claim 23 (depends on 1)

The method of claim 1, in which the glucoregulatory management recommendation is that the living subject ingest an amount of carbohydrate or inject glucagon.

### Claim 24 (depends on 23)

The method of claim 23, in which the amount of carbohydrate or amount of glucagon is based on an estimated net benefit calculation.

### Claim 25 (depends on 23)

The method of claim 23, in which the amount of carbohydrate or amount of glucagon is based on a linear regression model that correlates the amount of the carbohydrate with a predicted risk of hypoglycemia.
